Shopping Cart 0
Cart Subtotal
AED 0

Daiichi Sankyo Co Ltd (4568) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd (4568)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Daiichi Sankyo Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Daiichi Sankyo Co Ltd, Medical Equipment, Deal Details 11

Venture Financing 11

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 11

Partnerships 12

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 12

Daiichi Sankyo Partners with Nitto Denko 13

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 14

Equity Offering 15

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 15

Debt Offering 16

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 16

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 17

Asset Transactions 18

LYNCH Biologics Acquires Rights and Certain Assets of Luitpold Pharma 18

Acquisition 19

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 19

Daiichi Sankyo Co Ltd-Key Competitors 21

Daiichi Sankyo Co Ltd-Key Employees 22

Daiichi Sankyo Co Ltd-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Joint Venture 27

Recent Developments 28

Strategy And Business Planning 28

Aug 01, 2018: Daiichi Sankyo transfers 41 products to Alfresa Pharma 28

Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 29

Jan 09, 2018: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary 31

Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017 32

Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 33

Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 35

Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 37

Corporate Communications 38

May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 38

Feb 21, 2018: Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500) 39

Feb 02, 2018: Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018 40

Sep 15, 2017: Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index 41

Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers 42

Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 43

Legal and Regulatory 44

Jun 06, 2018: Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 44

Government and Public Interest 45

Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 45

Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 46

Other Significant Developments 47

Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 47

Jun 20, 2017: Daiichi Sankyo Selects Deloitte's ConvergeHEALTH Safety to Transform and Upgrade Global Drug Safety Platform 48

Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 49

Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Daiichi Sankyo Co Ltd, Medical Equipment, Key Facts, 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Daiichi Sankyo Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Daiichi Sankyo Co Ltd, Deals By Market, 2012 to YTD 2018 9

Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 11

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 12

Daiichi Sankyo Partners with Nitto Denko 13

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 14

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 15

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 16

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 17

LYNCH Biologics Acquires Rights and Certain Assets of Luitpold Pharma 18

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 19

Daiichi Sankyo Co Ltd, Key Competitors 21

Daiichi Sankyo Co Ltd, Key Employees 22

Daiichi Sankyo Co Ltd, Subsidiaries 24

Daiichi Sankyo Co Ltd, Joint Venture 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Daiichi Sankyo Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd (4568)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Daiichi Sankyo Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Daiichi Sankyo Co Ltd, Medical Equipment, Deal Details 11

Venture Financing 11

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 11

Partnerships 12

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 12

Daiichi Sankyo Partners with Nitto Denko 13

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 14

Equity Offering 15

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 15

Debt Offering 16

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 16

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 17

Asset Transactions 18

LYNCH Biologics Acquires Rights and Certain Assets of Luitpold Pharma 18

Acquisition 19

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 19

Daiichi Sankyo Co Ltd-Key Competitors 21

Daiichi Sankyo Co Ltd-Key Employees 22

Daiichi Sankyo Co Ltd-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Joint Venture 27

Recent Developments 28

Strategy And Business Planning 28

Aug 01, 2018: Daiichi Sankyo transfers 41 products to Alfresa Pharma 28

Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 29

Jan 09, 2018: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary 31

Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017 32

Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 33

Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 35

Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 37

Corporate Communications 38

May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 38

Feb 21, 2018: Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500) 39

Feb 02, 2018: Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018 40

Sep 15, 2017: Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index 41

Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers 42

Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 43

Legal and Regulatory 44

Jun 06, 2018: Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 44

Government and Public Interest 45

Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 45

Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 46

Other Significant Developments 47

Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 47

Jun 20, 2017: Daiichi Sankyo Selects Deloitte's ConvergeHEALTH Safety to Transform and Upgrade Global Drug Safety Platform 48

Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 49

Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Daiichi Sankyo Co Ltd, Medical Equipment, Key Facts, 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Daiichi Sankyo Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Daiichi Sankyo Co Ltd, Deals By Market, 2012 to YTD 2018 9

Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 11

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 12

Daiichi Sankyo Partners with Nitto Denko 13

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 14

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 15

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 16

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 17

LYNCH Biologics Acquires Rights and Certain Assets of Luitpold Pharma 18

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 19

Daiichi Sankyo Co Ltd, Key Competitors 21

Daiichi Sankyo Co Ltd, Key Employees 22

Daiichi Sankyo Co Ltd, Subsidiaries 24

Daiichi Sankyo Co Ltd, Joint Venture 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Daiichi Sankyo Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.